Last reviewed · How we verify
Cyanocobalamin Co 57 (cyanocobalamin (57Co))
At a glance
| Generic name | cyanocobalamin (57Co) |
|---|---|
| Sponsor | Mallinckrodt |
| Drug class | Radioactive Diagnostic Agent |
| Target | Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial, Methionine synthase, Methionine synthase reductase |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1968 |
Approved indications
- Cobalamin deficiency
- Iron deficiency anemia
- Megaloblastic anemia due to folate deficiency
- Pernicious anemia
- Prevention of Vitamin B12 Deficiency
- Vitamin Deficiency Prevention
- Vitamin deficiency
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyanocobalamin Co 57 CI brief — competitive landscape report
- Cyanocobalamin Co 57 updates RSS · CI watch RSS
- Mallinckrodt portfolio CI